Vaccination in Patients with Inflammatory Bowel Diseases | Zendy

Christine N. Manser | Zendy; Michel H. Maillard | Zendy; Gerhard Rogler | Zendy; Philipp Schreiner | Zendy; Florian Rieder | Zendy; Silja Bühler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vaccination in Patients with Inflammatory Bowel Diseases

Author(s) -

Christine N. Manser,

Michel H. Maillard,

Gerhard Rogler,

Philipp Schreiner,

Florian Rieder,

Silja Bühler

Publication year - 2020

Publication title -

digestion

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.882

H-Index - 75

eISSN - 1421-9867

pISSN - 0012-2823

DOI - 10.1159/000503253

Subject(s) - medicine , vedolizumab , vaccination , tofacitinib , ustekinumab , inflammatory bowel disease , immunology , janus kinase inhibitor , crohn's disease , disease , infliximab , intensive care medicine , rheumatoid arthritis

During the course of disease, a majority of inflammatory bowel disease (IBD) patients requires long-term immunosuppressive therapy with either immunomodulatory agents, biologics, or newer immunosuppressive therapies such as Vedolizumab, a selective α4β7 inhibitor, Ustekinumab, an IL 12/23 p40 inhibitor, or the Janus kinase inhibitor Tofacitinib. Due to this, they are at increased risk for infectious diseases, many of which are possible to prevent by vaccination. This review focuses on recommended vaccinations in IBD patients and stresses special issues which have to be paid attention to. The aim of the review is to increase gastroenterologists' awareness of the importance of vaccination and to stress why especially the gastroenterologist should assess the vaccination status of the patient and initiate vaccination as soon as diagnosis is established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research